Novo Nordisk's long-acting insulin Tresiba is set to gain new hypoglycaemia prevention claims in Europe, giving it an advantage over Sanofi’s top-selling Lantus. Europe's CHMP committee has just ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.